SanaGen was incorporated in 2019 and is headquartered at the New West Health & Innovation District in Amsterdam, The Netherlands. SanaGen focuses on gene therapy approaches for rare genetic disorders and other debilitating diseases which can provide a durable, even life-long cure. SanaGen is a pioneering company that focuses not just on gene therapy, but also on exploring creative ways to reduce development costs, with an intent to introduce unique sales and contracting models for getting products to patients, and production built to serve both developed and developing countries. The goal is to develop gene therapy treatments not just for the developed world, but all the world’s patients. SanaGen develops these new gene therapies in collaboration with the research group of Prof. dr. Jan Voorberg of Sanquin Research and Prof. dr. Joost Verhaagen of The Netherlands Institute of Neuroscience.
Our current portfolio includes the development of gene therapy for patients with factor VII and X deficiency. They are rare bleeding disorders which affect one in 300,000-500,000 people and current treatment for these disorders are suboptimal. Building on our extensive knowledge in the field of hemostasis as well as gene therapy development, we are also developing on gene therapy approaches for other bleeding disorders and liver-based genetic disorders. SanaGen aims to capitalize on over 3 decades of gene therapy research and experimentation, which has led to a rapidly innovating industry which is on the brink of treating many different genetic disorders.
SanaGen is founded and headed by David Mosmuller, MD PhD. He is a medical doctor with an entrepreneur mindset with extensive experience in clinical research, life sciences, medicine, regulatory affairs, and pharmacovigilance. The principal founders of SanaGen are experts in both basic and clinical studies on bleeding disorders and include experts with detailed knowledge on global markets for these disorders.